Before taking Canakinumab(ILARIS)

Requires vigilance for infections, hypersensitivity, and immunizations.

Risk Mitigation in Immunomodulatory Therapy

Serious Infections: Contraindicated in active infections; monitor for TB, opportunistic pathogens (e.g., aspergillosis). Discontinue if severe infection occurs.

Hypersensitivity: Immediate discontinuation for anaphylaxis or DRESS syndrome.

Immunizations: Avoid live vaccines; complete recommended vaccines pre-treatment.

Drug Interactions: Avoid concomitant TNF inhibitors (e.g., etanercept) or IL-1 blockers (e.g., anakinra) due to infection/neutropenia risks.

Pregnancy/Lactation: Limited data; consider placental transfer of IgG and infant immune risks.